Drug-induced pseudolymphoma and hypersensitivity syndrome. Two different clinical entities.

Drug-induced pseudolymphoma and hypersensitivity syndrome. Two different clinical entities. Research Abstract Details 

Research Abstract Table of Contents

Jump to the:

Drug-induced pseudolymphoma and hypersensitivity syndrome. Two different clinical entities. Abstract Text:

OBJECTIVE: To test the hypothesis that drug-induced pseudolymphoma and hypersensitivity syndrome are 2 distinct clinical entities. DESIGN: Retrospective study from 1980 to 1993. SETTING: Departments of dermatology and medicine of 5 referral universitary hospitals. PATIENTS: Twenty-four patients who met arbitrary criteria selected as being suggestive of lymphoma, with probable drug cause. Patients with other definite cutaneous drug-induced eruptions were excluded. INTERVENTION: None. MAIN OUTCOME MEASURES: Suspect drugs; clinical, biological, and pathological findings; and evolution of each case and of 110 published case reports. RESULTS: Two groups were separated according to their mode of onset and clinical aspect. Three patients (and 15 cases in the literature) had subacute papulonodular or infiltrated plaques, without visceral involvement. Skin biopsy specimens showed a dense lymphocytic infiltrate mimicking lymphoma. Healing was constant when the drug was stopped. The 21 remaining patients (and 95 published cases) had an acute widespread eruption, with fever, enlarged lymph nodes, and multivisceral involvement. Lymphocytosis, atypical lymphocytes, eosinophilia, hepatitis, and high levels of lactate dehydrogenase were frequent. Skin biopsy findings were usually not specific (lymphocytic infiltrate and keratinocyte necrosis) but sometimes mimicked lymphoma. Severe forms and relapses occurred, even after the drug was stopped. The inducing drugs were the same in the 2 groups. CONCLUSIONS: These 2 groups correspond to drug-induced pseudolymphoma and hypersensitivity syndrome. We think that they are 2 distinct entities with different clinical and biological features and outcome, even if the pathological findings are sometimes similar. Prospective studies are needed to confirm these facts, to evaluate the therapy, and to follow up patients.

Drug-induced pseudolymphoma and hypersensitivity syndrome. Two different clinical entities. Publishing Authors By Initials

For similar pathological conditions, signs and symptoms: pathologic processes: disease: syndrome research abstracts see: pathological conditions, signs and symptoms: pathologic processes: disease: syndrome research

PUBMED ID PMID:

MEDLINE DATE:

Drug-induced pseudolymphoma and hypersensitivity syndrome. Two different clinical entities. Journal Published:

PUBLICATION TYPE: Journal Article

Journal: Archives of dermatology

VOLUME: 132

Page Numbers: 1315-21

Journal Abbreviation: Arch Dermatol

ISSN: 0003-987X

DAY: 17

MONTH: Nov

YEAR: 1996

Drug-induced pseudolymphoma and hypersensitivity syndrome. Two different clinical entities. Information

Number of References:

LANGUAGE: eng

NlmUniqueID: 372433

Drug-induced pseudolymphoma and hypersensitivity syndrome. Two different clinical entities. Keywords Mesh Terms:

KEYWORDS: Syndrome

MESH TERMS: diagnosis

Chemical & Substance for Abstract: Drug-induced pseudolymphoma and hypersensitivity syndrome. Two different clinical entities. Information

Substance Name:

Registry Number:

Grant and Affiliation Information for Drug-induced pseudolymphoma and hypersensitivity syndrome. Two different clinical entities.

AFFILIATION: Department of Dermatology, Hôpital Henri Mondor, Creteil, France.

Country: UNITED STATES

AGENCY:

GRANT:

ACRONYM:

MEDLINETA: Arch Dermatol

REFSOURCE:

DATABASENAME:

ACCESSION NUMBER:

Number Hits: 0

Drug-induced pseudolymphoma and hypersensitivity syndrome Two different clinical entities Related Publications

• Drug-induced pseudolymphoma and hypersensitivity syndrome. Two different clinical entities.
• Eccrine syringofibroadenomatosis (Mascaro) with mucous involvement.
• French people and skin diseases: results of a survey using a representative sample.
• Impaired antigen presentation in toxic epidermal necrolysis.
• More on the frequency of segmental neurofibromatosis.
• Severe cutaneous reactions to self-defense sprays.
• Thalidomide neuropathy incidence and clinico-electrophysiologic findings in 42 patients.
• The global dermatological village in Paris.
• The significance of a single periungual fibroma: report of seven cases.
• Transient intraepidermal bullous reaction after skin graft for toxic epidermal necrolysis. Ultrastructural and immunohistochemical features similar to those of inherited epidermolysis bullosa simplex.
• Usefulness of screening investigations in neurofibromatosis type 1. A study of 152 patients.
• [Thalidomide.]